Skip to main content

Advertisement

Table 1 Questionnaire on the first-line use of pazopanib in clinical practice

From: Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma

  Question Response options
1a Is achieving a complete response or a partial response with pazopanib in first-line treatment directly correlated with better OSa? 1 (strongly disagree) 4 (strongly agree)
1b Is achieving a complete or partial response with pazopanib in first-line treatment directly correlated with better PFSb? 1 (strongly disagree) 4 (strongly agree)
2 Even if there is no impact on OS, is the longer PFS in first-line treatment with pazopanib sufficient for it to be considered as a standard treatment option? 1 (strongly disagree) 4 (strongly agree)
3 Should OS be considered as a primary objective in first-line studies? a) Yes b) No
4 When selecting pazopanib as a first-line treatment, to which parameter do you give more importance in daily clinical practice? a) OS b) PFS c) cQoL
5 Does reducing the dose of pazopanib compromise its efficacy? 1 (strongly disagree) 4 (strongly agree)
6 When prescribing a treatment, do you inform the patient about the different first-line treatment options in order to take into account their opinion and preference? 1 (strongly disagree) 4 (strongly agree)
7a Is pazopanib an appropriate first-line treatment for patients with clear cell carcinoma, ECOGd 0, and no significant comorbidities? 1 (strongly disagree) 4 (strongly agree)
7b Is pazopanib an appropriate first-line treatment for patients with brain metastases? 1 (strongly disagree) 4 (strongly agree)
7c Is pazopanib an appropriate first-line treatment for patients with concomitant cardiovascular disease? 1 (strongly disagree) 4 (strongly agree)
7d Is pazopanib an appropriate first-line treatment for patients with concomitant liver disease? 1 (strongly disagree) 4 (strongly agree)
7e Is pazopanib an appropriate first-line treatment for patients with non-clear cell histologies? 1 (strongly disagree) 4 (strongly agree)
7f Is pazopanib an appropriate first-line treatment for patients with moderate to severe renal failure (CrCle ≤ 30)? 1 (strongly disagree) 4 (strongly agree)
7 g Is pazopanib an appropriate first-line treatment for patients with ECOG ≥2? 1 (strongly disagree) 4 (strongly agree)
7e Is pazopanib an appropriate first-line treatment for patients with a poor prognosis? 1 (strongly disagree) 4 (strongly agree)
7f Is pazopanib an appropriate first-line treatment for patients with asymptomatic heart disease and fLVEF < 50%? 1 (strongly disagree) 4 (strongly agree)
8 When starting treatment with pazopanib in patients treated with oral anticoagulants, what do you do in your standard clinical practice? a) Change treatment to gLMWH b) Continue hOAC treatment
9a With regard to patient age and pazopanib treatment, indicate your level of agreement with the following statement: “I do not prescribe pazopanib in patients older than 80 years of age” 1 (strongly disagree) 4 (strongly agree)
9b With regard to patient age and pazopanib treatment, indicate your level of agreement with the following statement: “In patients over 70 years of age, I prescribe treatment at a dose of 800 mg/day”. 1 (strongly disagree) 4 (strongly agree)
10 If biomarkers for pazopanib response were available, which would be most useful for you in your daily clinical practice? a) Biomarkers predicting toxicity b) Biomarkers predicting efficacy
11 With regard to tolerability, place in order of importance, from highest to lowest, the following factors to be taken into account when prescribing pazopanib. a) Functional status b) Concomitant diseases c) Age d) Social support
12 Is it advisable to temporarily suspend treatment with pazopanib, and to continue with radiological monitoring, in order to reduce pazopanib toxicity (stop-and-go strategy)? 1 (strongly disagree) 4 (strongly agree)
13a If pazopanib toxicity develops, what do you do in the case of grade 2 gastrointestinal toxicity? a) Maintain the dose b) Reduce the dose c) Discontinue treatment
13b If pazopanib toxicity develops, what do you do in the case of grade 3–4 gastrointestinal toxicity? a) Maintain the dose b) Reduce the dose c) Discontinue treatment
13c If pazopanib toxicity develops, what do you do in the case of grade 1–2 liver toxicity (AST/ALT 2.5 times the normal value)? a) Maintain the dose b) Reduce the dose c) Discontinue treatment
14 If the patient shows complete response to pazopanib, what do you do in your standard clinical practice? a) Maintain the dose b) Adjust the therapeutic regimen c) Discontinue treatment
  1. aOS: overall survival; bPFS: progression-free survival; cQoL: quality of life; dECOG: Eastern Cooperative Oncology Group; eCrCl: creatinine clearance; fLVEF: left ventricular ejection fraction; gLWMH: low molecular weight heparin; hOAC: oral anticoagulants